Full Description
The book delves into the development and therapeutic potential of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of diabetes and cardiovascular diseases. It explores their mechanism of action, cardiovascular benefits, and role in primary and secondary protection from renal and cardiovascular diseases. The book also highlights their emerging opportunities in the management of myocardial infarction, diabetic cardiomyopathy, and congestive heart failure. It provides a comprehensive review of preclinical and clinical information on the cardiovascular advantages of SGLT2 inhibitors. Additionally, the book explores selective drugs and their effects on cardiovascular events, mortality, and safety outcomes in individuals with type 2 diabetes.
The book is a valuable resource for researchers, healthcare professionals, and individuals interested in the field of SGLT2 inhibitors and their impact on diabetes and cardiovascular health.
Contents
Chapter 1_ The History of the Development of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors for the Treatment of Diabetes: from biology to Chemistry.- Chapter 2_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors and mechanism of cardiovascular benefits in type 2 diabetes .- Chapter 3_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for primary and secondary protection from cardiovascular and renal diseases in Type 2 diabetes.- Chapter 4_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors: Emerging opportunities for the treatment of myocardial infarction.- Chapter 5_ Potential Role of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment and Prevention of Diabetic Cardiomyopathy.- Chapter 6_ Contemporary Management, unmet needs, and Therapeutic Potential of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in congestive heart failure.- Chapter 7 A comprehensive review of preclinical and clinical information on the cardiovascular advantages of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors.- Chapter 8_ Exploring the current selective drugs of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of cardiovascular disease in Type 2 Diabetes.- Chapter 9_ A comprehensive review of Sodium-glucose Cotransporter-2 (SGLT2) inhibitor's effects on cardiovascular events, mortality, and significant safety outcomes in individuals with type 2 diabetes.
